COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #82 of 258
7/10 Late treatment study
Chen et al., PLOS ONE, doi:10.1371/journal.pone.0242763 (Peer Reviewed)
A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)
Source   PDF   Share   Tweet
2 very small studies with hospitalized patients in Taiwan.
RCT with 21 treatment and 12 SOC patients. No mortality, or serious adverse effects. Median time to negative RNA 5 days versus 10 days SOC, p=0.4. Risk of PCR+ at day 14, RR 0.76, p = 0.71.
This paper also reports on a small retrospective study with 12 of 28 HCQ patients and 5 of 9 in the control group being PCR- at day 14, RR 1.29, p = 0.7.

Chen et al., 7/10/2020, Randomized Controlled Trial, Taiwan, Asia, peer-reviewed, 19 authors.
risk of no virological cure, 24.0% lower, RR 0.76, p = 0.71, treatment 4 of 21 (19.0%), control 3 of 12 (25.0%), day 14.
median time to PCR-, 50.0% lower, relative time 0.50, p = 0.40, treatment 21, control 12.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit